| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.074 | 0.04 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.09 | 0.04 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.31 | 0.04 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.05 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.069 | 0.05 |
| mRNA | Bicalutamide | FIMM | pan-cancer | AAC | 0.34 | 0.05 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | -0.29 | 0.05 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | -0.091 | 0.05 |
| mRNA | AGK-2 | CTRPv2 | pan-cancer | AAC | 0.072 | 0.05 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.071 | 0.05 |